Enovix / Rodgers Silicon Valley Acquisition Corp. — Q1 2021 Form 10-Q
Reporting entity: The filing is for Rodgers Silicon Valley Acquisition Corp. (RSVA), a blank-check company, not Enovix Corporation’s standalone financial statements. It covers the quarter ended March 31, 2021; the financial statements are unaudited. RSVA had not begun operating activities and had no operating revenue.
Business context
On February 22, 2021, RSVA agreed to merge with Enovix, with Enovix surviving as RSVA’s wholly owned subsidiary. The agreement provided for 105 million RSVA shares to be issued or reserved for Enovix shares and vested equity awards, with additional shares reserved for unvested options. The transaction remained subject to completion and shareholder redemption rights. RSVA’s deadline to complete a business combination was December 4, 2022.
Financial results and liquidity
| Metric | Q1 2021 / March 31, 2021 | Comparison / context |
|---|---|---|
| Revenue | None | RSVA expected no operating revenue before a business combination. |
| Operating costs / operating loss | $579,343 | Formation, public-company and transaction-related costs. |
| Net loss | $51.35 million | Primarily driven by a $50.845 million noncash increase in warrant liability fair value. |
| Trust interest and unrealized gain | $61,910 interest; $9,455 unrealized gain | Trust assets were primarily money-market investments and U.S. government securities. |
| Cash outside trust | $305,093 | Down from $773,086 at December 31, 2020. |
| Cash and securities in trust | $230.02 million | Restricted principally for a business combination or shareholder redemptions. |
| Total assets | $230.50 million | Compared with $230.91 million at December 31, 2020. |
| Warrant liability | $70.625 million | Up from $19.780 million at December 31, 2020; reported as a current liability. |
| Deferred underwriting fee | $8.05 million | Payable from trust funds only if a business combination closes. |
| Operating cash flow | $(490,285) | Investing cash flow was $22,292; financing cash flow was zero. |
Net loss per share for non-redeemable common stock is reported as $(5.74) in the statement of operations and $(5.75) in the earnings-per-share note; the filing text is inconsistent on this value. No gross margin, operating margin or debt balance is presented. RSVA reported $5.0 million of stockholders’ equity and $146.64 million of common stock subject to possible redemption at quarter-end.
Changes, outlook and risks
- The main change in reported results was the sharp rise in warrant fair value, which accounted for nearly all of the quarterly loss and was noncash. The filing does not provide a comparable Q1 2020 income statement.
- RSVA said it intended to use substantially all trust funds toward a business combination. It disclosed no specific operating or financial guidance for Enovix.
- Management discussed possible need for additional working capital or transaction financing if costs exceeded estimates or redemptions were significant. The notes say liquidity conditions raised substantial doubt about RSVA’s ability to continue as a going concern; the MD&A says it did not believe additional funds would be needed for expected expenditures, while acknowledging financing might be required.
- Two lawsuits alleged fiduciary-duty breaches and deficient or misleading transaction disclosures, and sought monetary and injunctive relief, including an effort to enjoin the proposed merger. RSVA said it could not estimate possible losses, considered the claims without merit and intended to defend them.
- Management concluded disclosure controls were ineffective because of a material weakness involving insufficient independent review of technical accounting matters. Remediation actions were underway, but the weakness remained as of March 31, 2021.
- RSVA cited COVID-19-related uncertainty as a potential impediment to identifying, negotiating and completing a transaction. It reported no material changes to risk factors in its May 10, 2021 Form S-4 amendment.
Important facts for investors to verify
- Merger status, closing conditions, share issuance and the potential effect of public-share redemptions on cash available to the combined company.
- Enovix’s standalone financial results, cash needs, production plans and outlook; they are not provided in this RSVA quarterly filing.
- The warrant valuation and the resulting $50.845 million noncash expense, including the assumptions used for private-placement warrants.
- RSVA’s limited unrestricted cash, going-concern disclosure and any additional financing or related-party loans.
- The status and potential consequences of the transaction-related lawsuits and the remediation of the reported internal-control material weakness.
- The inconsistent $(5.74) versus $(5.75) loss-per-share presentation and the precise share counts subject to redemption.